Avalon Globocare Corp
ALBT1.960USD
-0.130-6.22%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
4.60MMarket Cap
LossP/E TTM
More Details of Avalon Globocare Corp Company
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.
Avalon Globocare Corp Info
Ticker SymbolALBT
Company nameAvalon Globocare Corp
IPO dateFeb 22, 2016
CEODr. David Jin, M.D., Ph.D.
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 22
Address4400 Route 9
CityFREEHOLD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07728
Phone17327804400
Websitehttps://www.avalon-globocare.com/
Ticker SymbolALBT
IPO dateFeb 22, 2016
CEODr. David Jin, M.D., Ph.D.
Company Executives of Avalon Globocare Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Company Secretary
Chief Operating Officer, Company Secretary
34.33K
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Wilbert J. (Billy) Tauzin, II
Mr. Wilbert J. (Billy) Tauzin, II
Director
Director
--
--
Dr. The Hon. Tevi Troy, Ph.D.
Dr. The Hon. Tevi Troy, Ph.D.
Independent Director
Independent Director
--
--
Mr. William B. Stilley, III
Mr. William B. Stilley, III
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Company Secretary
Chief Operating Officer, Company Secretary
34.33K
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 3
Updated: Wed, Sep 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lu (Wenzhao)
6.23%
Jin (David)
2.69%
Vision Capital NY, Inc.
2.61%
Li (Meng)
0.90%
Geode Capital Management, L.L.C.
0.54%
Other
87.05%
Shareholders
Shareholders
Proportion
Lu (Wenzhao)
6.23%
Jin (David)
2.69%
Vision Capital NY, Inc.
2.61%
Li (Meng)
0.90%
Geode Capital Management, L.L.C.
0.54%
Other
87.05%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.84%
Corporation
2.61%
Investment Advisor
0.66%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.03%
Other
86.33%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
47.28K
1.23%
-3.08K
2025Q2
37
494.33K
14.25%
+85.10K
2025Q1
39
494.33K
24.18%
+84.18K
2024Q4
39
426.83K
39.01%
+28.37K
2024Q3
38
465.14K
44.22%
+32.28K
2024Q2
37
431.58K
58.50%
+7.86K
2024Q1
35
421.26K
56.90%
-5.41K
2023Q4
36
425.06K
58.60%
-685.00
2023Q3
43
423.55K
58.41%
-5.26K
2023Q2
52
423.10K
61.82%
-6.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lu (Wenzhao)
238.93K
6.23%
+9.00
+0.00%
Mar 31, 2025
Jin (David)
103.00K
2.69%
--
--
Mar 31, 2025
Vision Capital NY, Inc.
100.00K
2.61%
+100.00K
--
Mar 31, 2025
Li (Meng)
34.33K
0.9%
+1.00
+0.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
9.34K
0.24%
--
--
Aug 31, 2025
Equitable Holdings, Inc.
14.22K
0.37%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.58K
0.04%
--
--
Aug 31, 2025
UBS Financial Services, Inc.
4.20K
0.11%
+1.64K
+64.05%
Jun 30, 2025
Tauzin (Wilbert J II)
1.04K
0.03%
+1.04K
--
Mar 31, 2025
Citi Investment Research (US)
951.00
0.02%
+951.00
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Date
Type
Ratio
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
